口服泼尼松龙与地塞米松在沙特和英国儿童中的适口性与耐受性观察研究
该前瞻性观察/访谈研究在沙特阿拉伯和英国各进行3个月,评估儿童口服短程皮质类固醇的适口性与耐受性。结果显示地塞米松制剂适口性评分最高,泼尼松龙碱基片最低且耐受性最差,所有泼尼松龙制剂适口性随每日给药次数增加而改善。
要点
- 地塞米松制剂适口性评分最高,泼尼松龙碱基片最低。
- 泼尼松龙碱基片恶心呕吐等不良反应较多,耐受性最差。
- 所有泼尼松龙制剂适口性评分随每日给药次数增加而改善。
核心结论
- 地塞米松磷酸钠溶液适口性最佳,泼尼松龙碱基片适口性最差且耐受性最差。
- 泼尼松龙制剂适口性评分随每日给药次数增加而改善。
研究设计与样本
- 前瞻性观察/访谈研究,在沙特阿拉伯和英国各进行3个月。
- 沙特阿拉伯纳入122例2-10岁患者,英国纳入133例2-16岁患者。
主要发现
- 沙特阿拉伯:地塞米松酏剂适口性评分均值1.97,泼尼松龙碱基片1.12。
- 英国:地塞米松磷酸钠口服溶液适口性评分均值3,泼尼松龙碱基片1.39。
- 沙特阿拉伯:泼尼松龙碱基片较磷酸钠糖浆更多恶心(24 vs 7例,p=0.008)和呕吐(5 vs 0例,p=0.073)。
- 英国:泼尼松龙碱基片较磷酸钠可溶片更多呕吐(8 vs 2例,p=0.041)。
- 两地地塞米松副作用较少;地塞米松磷酸钠溶液较酏剂更多呕吐(1 vs 0例)、恶心(7 vs 3例)和腹痛(10 vs 8例)。
临床怎么用
- 临床选择口服皮质类固醇时,可优先考虑适口性更高、耐受性更好的地塞米松制剂。
- 使用泼尼松龙碱基片时需关注恶心、呕吐等不良反应。
- 重复给药可能改善泼尼松龙制剂的适口性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Short-course oral corticosteroids are routinely used to treat acute asthma and croup. We evaluated their tolerability and palatability in Saudi Arabian (SA) and UK children. METHODS: Prospective observational/interview study (3 months in each country). Palatability was evaluated using a 5-point facial Hedonicscale and tolerability by direct questioning of patient/parents. RESULTS: In SA, of 122 patients (2-10 years) recruited, 52 received prednisolone base tablets, 37 prednisolone sodium phosphate syrup and 33 received dexamethasone elixir. In the UK, of 133 patients (2-16 years), 38 received prednisolone base tablets (mainly crushed and dispersed), 42 prednisolone sodium phosphate soluble tablets and 53 received dexamethasone sodium phosphate oral solution.In both countries, dexamethasone had the highest palatability scores (SA mean: 1.97; UK mean: 3) and prednisolone base tablets had the lowest (SA mean: 1.12; UK mean: 1.39). Palatability scores improved for all formulations of prednisolone with each subsequent daily dose.In SA, prednisolone base tablets were associated with more nausea (24vs7 patients) and vomiting (5vs0 patients) than sodium phosphate syrup (p=0.008 and p=0.073, respectively). In the UK, vomiting occurred more frequently with prednisolone base (8 patients) than sodium phosphate soluble tablets (2 patients) (p=0.041).In both centres, dexamethasone was associated with less side effects. Vomiting (1vs0 patients), nausea (7vs3 patients) and abdominal pain (10vs8 patients) occurred more with dexamethasone sodium phosphate solution than dexamethasone elixir. CONCLUSIONS: Dexamethasone sodium phosphate solution was the most palatable preparation. Prednisolone base tablets were rated least palatable and were least well tolerated. Palatability scores improved with each dose taken.
引用
- Aljebab F, Alanazi M, Choonara I, et al. Observational study on the palatability and tolerability of oral prednisolone and oral dexamethasone in children in Saudi Arabia and the UK. Arch Dis Child. 2017. PMID: 28735259. doi:10.1136/archdischild-2017-312697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。